Advertisement
New Zealand markets closed
  • NZX 50

    11,741.47
    -21.85 (-0.19%)
     
  • NZD/USD

    0.6105
    +0.0004 (+0.07%)
     
  • NZD/EUR

    0.5631
    +0.0007 (+0.12%)
     
  • ALL ORDS

    7,954.30
    +37.20 (+0.47%)
     
  • ASX 200

    7,695.90
    +35.50 (+0.46%)
     
  • OIL

    78.48
    -0.06 (-0.08%)
     
  • GOLD

    2,044.20
    +1.50 (+0.07%)
     
  • NASDAQ

    17,874.50
    -96.54 (-0.54%)
     
  • FTSE

    7,624.98
    -58.04 (-0.76%)
     
  • Dow Jones

    38,949.02
    -23.39 (-0.06%)
     
  • DAX

    17,601.22
    +44.73 (+0.25%)
     
  • Hang Seng

    16,561.53
    +24.68 (+0.15%)
     
  • NIKKEI 225

    39,072.22
    -135.81 (-0.35%)
     
  • NZD/JPY

    91.4720
    -0.4050 (-0.44%)
     

Will Bionomics (ASX:BNO) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So should Bionomics (ASX:BNO) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

View our latest analysis for Bionomics

When Might Bionomics Run Out Of Money?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Bionomics last reported its balance sheet in June 2022, it had zero debt and cash worth AU$34m. Looking at the last year, the company burnt through AU$22m. So it had a cash runway of approximately 19 months from June 2022. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. Importantly, if we extrapolate recent cash burn trends, the cash runway would be a lot longer. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Bionomics' Cash Burn Changing Over Time?

In the last year, Bionomics did book revenue of AU$6.1m, but its revenue from operations was less, at just AU$264k. Given how low that operating leverage is, we think it's too early to put much weight on the revenue growth, so we'll focus on how the cash burn is changing, instead. The skyrocketing cash burn up 189% year on year certainly tests our nerves. It's fair to say that sort of rate of increase cannot be maintained for very long, without putting pressure on the balance sheet. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Hard Would It Be For Bionomics To Raise More Cash For Growth?

While Bionomics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Bionomics' cash burn of AU$22m is about 48% of its AU$46m market capitalisation. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising.

How Risky Is Bionomics' Cash Burn Situation?

On this analysis of Bionomics' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Summing up, we think the Bionomics' cash burn is a risk, based on the factors we mentioned in this article. Separately, we looked at different risks affecting the company and spotted 6 warning signs for Bionomics (of which 1 shouldn't be ignored!) you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here